A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors
Latest Information Update: 12 Sep 2024
At a glance
- Drugs ORM 2110 (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALPHAMEDIX02
- Sponsors RadioMedix
- 12 Sep 2024 According to a RadioMedix media release, AlphaMedix is currently completing phase 2 clinical development, and the data is being discussed with the FDA for potential regulatory filing and approval.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 12 Feb 2024 According to a RadioMedix media release, the United States FDA has granted Breakthrough Therapy Designation to AlphaMedixTM (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naive to peptide receptor radionuclide therapy based on results from phase 1 and the ongoing phase 2 clinical trials that assessed the safety and efficacy of AlphaMedixTM.